ERMA Stock Overview
A pharmaceutical company, produces and supplies medical chewing gum and other nicotine products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Enorama Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.36 |
| 52 Week High | SEK 10.50 |
| 52 Week Low | SEK 2.00 |
| Beta | 1.54 |
| 1 Month Change | -2.89% |
| 3 Month Change | -22.40% |
| 1 Year Change | 8.39% |
| 3 Year Change | -86.48% |
| 5 Year Change | -91.88% |
| Change since IPO | -57.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERMA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 9.8% | -0.4% | 0.6% |
| 1Y | 8.4% | -5.0% | 4.2% |
Return vs Industry: ERMA exceeded the Swedish Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: ERMA exceeded the Swedish Market which returned 4.5% over the past year.
Price Volatility
| ERMA volatility | |
|---|---|
| ERMA Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 8.9% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ERMA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ERMA's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 5 | Daniel Schroder | www.enorama.se |
Enorama Pharma AB (publ), a pharmaceutical company, produces and supplies medical chewing gum and other nicotine products. It also offers nicotine pouches and medical cannabis products. Enorama Pharma AB (publ) was incorporated in 2006 and is based in Malmö, Sweden.
Enorama Pharma AB (publ) Fundamentals Summary
| ERMA fundamental statistics | |
|---|---|
| Market cap | SEK 203.19m |
| Earnings (TTM) | -SEK 35.55m |
| Revenue (TTM) | SEK 13.30m |
15.3x
P/S Ratio-5.7x
P/E RatioIs ERMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERMA income statement (TTM) | |
|---|---|
| Revenue | SEK 13.30m |
| Cost of Revenue | SEK 10.07m |
| Gross Profit | SEK 3.23m |
| Other Expenses | SEK 38.77m |
| Earnings | -SEK 35.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 24.25% |
| Net Profit Margin | -267.30% |
| Debt/Equity Ratio | 1.0% |
How did ERMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:47 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enorama Pharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|